Hematopoietic Stem Cell Transplantation Therapeutic Market Pipeline Overview, Key Players & Drugs Profiles H2 2014

Share Article

RnRMarketResearch.com adds "Hematopoietic Stem Cell Transplantation – Pipeline Review, H2 2014" to its store. This report provides an overview of the Hematopoietic Stem Cell Transplantation therapeutic pipeline.

Hematopoietic Stem Cell Transplantation Therapeutic Pipeline Market

Hematopoietic Stem Cell Transplantation Therapeutic Pipeline Market

The report “Hematopoietic Stem Cell Transplantation – Pipeline Review, H2 2014” provides comprehensive information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/hematopoietic-stem-cell-transplantation-pipeline-review-h2-2014-market-report.html .

Companies Involved in Hematopoietic Stem Cell Transplantation Therapeutics Development are:
Actinium Pharmaceuticals, Inc., Athersys, Inc., BioLineRx, Ltd., Celldex Therapeutics, Inc., Cellerant Therapeutics, Inc., Hospira, Inc., Kiadis Pharma B.V., MediPost Co., Ltd., Novartis AG, Pharmalink AB, Polyphor Ltd., Recoly N.V., TaiGen Biotechnology Co., Ltd., Targazyme, Inc. and TikoMed AB.

The report “Hematopoietic Stem Cell Transplantation – Pipeline Review, H2 2014” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Order a Purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=239928 .

The report “Hematopoietic Stem Cell Transplantation – Pipeline Review, H2 2014” provides below Drugs Profile information on Actimab-B, ATIR, BL-8040, burixafor, busulfan liposomal IR, CDX-301, CordSafe, filgrastim, HSC-835, Iomab-B, MultiStem, NecLip-G-CSF, POL-5551, POL-6326, Promostem, romyelocel-L, TM-400, TXA-127 and TZ-101.

Scope of this report as follows: The report provides a snapshot of the global therapeutic landscape of Hematopoietic Stem Cell Transplantation. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. The report reviews key players involved in the therapeutics development for Hematopoietic Stem Cell Transplantation and enlists all their major and minor projects. The report summarizes all the dormant and discontinued pipeline projects. A review of the Hematopoietic Stem Cell Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. A detailed assessment of monotherapy and combination therapy pipeline projects. Coverage of the Hematopoietic Stem Cell Transplantation pipeline on the basis of target, MoA, route of administration and molecule type. Latest news and deals relating related to pipeline products. Inquire Before Buying @ http://www.rnrmarketresearch.com/contacts/discount?rname=239928 . (This is a premium report priced at US$2000 for a single user License.)

Reasons to buy the report "Sepsis – Pipeline Review, H2 2014": Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Develop strategic initiatives by understanding the focus areas of leading companies. Identify and understand important and diverse types of therapeutics under development for Rabies. Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. Devise corrective measures for pipeline projects by understanding Rabies pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore more reports on Pharmaceuticals industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .

About Us:
Rnrmarketresearch.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
Sandler Research
since: 04/2014
Like >
Follow us on
Visit website